AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33272295 — intervention group
Group type: EXPERIMENTAL
Intervention: C-HDL (in-vitro carbamylated HDL)
Number of subjects: 148
Study 33272295 — intervention group
Group type: COMPARATOR
Intervention: HDL-CBL level in T2DM patients
Number of subjects: 148
Study 33272295 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-CBL level in T2DM patients with CAD
Number of subjects: 148
Study 33272295 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HDL-CBL level
Number of subjects: 148
Study 33272982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Infliximab (5 mg/kg)
Number of subjects: 14
Study 33272982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Certolizumab
Number of subjects: 14
Study 33273034 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant-specific loss of heterozygosity (LOH) analysis
Number of subjects: 0
Study 33273214 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 274
Study 33273317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional cohort (CSC)
Number of subjects: 1027
Study 33273317 — intervention group
Group type: COMPARATOR
Intervention: Prospective cohort (PC)
Number of subjects: 1027
Study 33273485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spot (DBS) sampling and CRP test regime
Number of subjects: 100
Study 33273485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous weekly DBS CRP data
Number of subjects: 100
Study 33273485 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal baseline and 6 week sample CRP data
Number of subjects: 100
Study 33273485 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS ELISA assay CRP measures
Number of subjects: 100
Study 33273742 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4482/EIDD-2801, dosage and duration not specified
Number of subjects: 0
Study 33274309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PomJ)
Number of subjects: 20
Study 33274309 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (PL)
Number of subjects: 20
Study 33274349 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced modulation
Number of subjects: 0
Study 33274416 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19
Number of subjects: 213
Study 33274416 — intervention group
Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 213
Study 33274648 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33274668 — intervention group
Group type: EXPERIMENTAL
Intervention: Detail and Flexibility Questionnaire (DFlex)
Number of subjects: 0
Study 33274726 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mobile app with text, voice, video, and pictorial messages regarding routine childhood immunization (RCI)
Number of subjects: 0
Study 33274726 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33274751 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead (BL) ratio in the digit-symbol test (DST) cohort
Number of subjects: 260
Study 33274751 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead (BL) ratio in the Stroop test (ST) cohort
Number of subjects: 260
Study 33274751 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in DST and ST test results with blood lead changes
Number of subjects: 260
Study 33275104 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter + Fitbit treatment group
Number of subjects: 45
Study 33275104 — intervention group
Group type: COMPARATOR
Intervention: Fitbit-only control group
Number of subjects: 45
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive goals with immediate reinforcement
Number of subjects: 512
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive goals with delayed reinforcement
Number of subjects: 512
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: Static goals with immediate reinforcement
Number of subjects: 512
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: Static goals with delayed reinforcement
Number of subjects: 512
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 512
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation walking
Number of subjects: 512
Study 33275107 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure walking
Number of subjects: 512
Study 33275200 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation PF-SES
Number of subjects: 643
Study 33275200 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation PF-SES
Number of subjects: 643
Study 33275278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 576
Study 33275278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium
Number of subjects: 576
Study 33275278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B
Number of subjects: 576
Study 33275278 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin D
Number of subjects: 576
Study 33275278 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium-vitamin D
Number of subjects: 576
Study 33275450 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 0
Study 33275486 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ADT
Number of subjects: 1065
Study 33275486 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant ADT
Number of subjects: 1065
Study 33276117 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 inflammation treatment
Number of subjects: 0
Study 33276302 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for ICAD
Number of subjects: 105
Study 33276302 — intervention group
Group type: EXPERIMENTAL
Intervention: QMRA
Number of subjects: 105
Study 33276302 — intervention group
Group type: EXPERIMENTAL
Intervention: PWI
Number of subjects: 105
Study 33276302 — intervention group
Group type: EXPERIMENTAL
Intervention: VMR
Number of subjects: 105
Study 33276302 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS
Number of subjects: 105
Study 33276318 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp video consultation
Number of subjects: 144
Study 33276318 — intervention group
Group type: COMPARATOR
Intervention: Bedside consultation
Number of subjects: 144
Study 33276423 — intervention group
Group type: EXPERIMENTAL
Intervention: two-visit primary vaccination schedule (two intradermal 0.1 mL rabies vaccine doses on day 0 and 7)
Number of subjects: 500
Study 33276423 — intervention group
Group type: COMPARATOR
Intervention: three-visit primary vaccination schedule (single intradermal 0.1 mL dose on day 0, 7, and 28)
Number of subjects: 500
Study 33276773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 6
Study 33276773 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-Touch intervention
Number of subjects: 6
Study 33277059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 8687
Study 33277073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total menaquinones (MKs) intake
Number of subjects: 2286
Study 33277223 — intervention group
Group type: EXPERIMENTAL
Intervention: LAG-3 expression in HRS cells
Number of subjects: 57
Study 33277223 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM-3 expression in HRS cells
Number of subjects: 57
Study 33277223 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 expression in microenvironment
Number of subjects: 57
Study 33277223 — intervention group
Group type: EXPERIMENTAL
Intervention: LAG-3 expression in microenvironment
Number of subjects: 57
Study 33277223 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM-3 expression in microenvironment
Number of subjects: 57
Study 33277290 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective survival (primary outcome)
Number of subjects: 4752
Study 33277290 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (secondary outcome)
Number of subjects: 4752
Study 33277290 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of disease progression (secondary outcome)
Number of subjects: 4752
Study 33277400 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33277427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs), 3 injections spaced 3 months apart.
Number of subjects: 20
Study 33277427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs).
Number of subjects: 20
Study 33277620 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDL induction chemotherapy (4 cycles)
Number of subjects: 27
Study 33277620 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront autologous stem cell transplantation (ASCT)
Number of subjects: 27
Study 33277620 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDL induction chemotherapy
Number of subjects: 27
Study 33277620 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 27
Study 33277913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive therapy (73.7% of recipients)
Number of subjects: 1191
Study 33277913 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin-based immunosuppressive therapy (24.3% of recipients)
Number of subjects: 1191
Study 33277913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive therapy
Number of subjects: 1191
Study 33277913 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin-based immunosuppressive therapy
Number of subjects: 1191
Study 33277991 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiously tailored text messages (two per day)
Number of subjects: 50
Study 33277991 — intervention group
Group type: COMPARATOR
Intervention: Non-religiously tailored text messages (two per day)
Number of subjects: 50
Study 33278016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Number of subjects: 363
Study 33278016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Number of subjects: 363
Study 33278016 — intervention group
Group type: COMPARATOR
Intervention: Placebo re-randomized to ixekizumab
Number of subjects: 363
Study 33278016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (All Exposure Safety Population)
Number of subjects: 363
Study 33278077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based immunotherapy
Number of subjects: 0
Study 33278077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel approaches using innate immune system cells
Number of subjects: 0
Study 33278077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based therapies
Number of subjects: 0
Study 33278125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose synthetic ACTH
Number of subjects: 0
Study 33278125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose synthetic ACTH
Number of subjects: 0
Study 33278125 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 and 30-min serum or salivary cortisol levels
Number of subjects: 0
Study 33278125 — intervention group
Group type: EXPERIMENTAL
Intervention: New hydrocortisone formulations and delivery methods
Number of subjects: 0
Study 33278125 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications in combination with hydrocortisone
Number of subjects: 0
Study 33278131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 23
Study 33278297 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cannabis users
Number of subjects: 3426
Study 33278297 — intervention group
Group type: COMPARATOR
Intervention: Current cannabis users pre-legalization
Number of subjects: 3426
Study 33278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand training
Number of subjects: 22
Study 33278365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonweight-bearing arm crank ergometry
Number of subjects: 22
Study 33278365 — intervention group
Group type: COMPARATOR
Intervention: Locomotor training (previously published data, N=7)
Number of subjects: 22
Study 33278600 — intervention group
Group type: EXPERIMENTAL
Intervention: High SDmax (> 0.32 m)
Number of subjects: 290
Study 33278600 — intervention group
Group type: COMPARATOR
Intervention: Low SDmax (≤ 0.32 m)
Number of subjects: 290
Study 33278656 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable intake
Number of subjects: 600
Study 33278656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark leafy greens and berries/melons intake
Number of subjects: 600
Study 33278792 — intervention group
Group type: EXPERIMENTAL
Intervention: imILT protocol treatment using TRANBERG|Thermal Therapy System
Number of subjects: 15
Study 33279368 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach education intervention
Number of subjects: 44
Study 33279876 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average stress score (measured using the 4-item perceived stress scale)
Number of subjects: 1060
Study 33279887 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (20 mg oral, weeks 1 and 2), Bortezomib (1.3 mg/m2 subcutaneous, days 1, 4, 8, and 11), Dexamethasone (20 mg oral, day of and the day following bortezomib administration) for 8 cycles (24 weeks)
Number of subjects: 31
Study 33279887 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat, Bortezomib, Dexamethasone (extension phase)
Number of subjects: 31
Study 33279887 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat, Bortezomib, Dexamethasone
Number of subjects: 31
Study 33280027 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study 33280227 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal (ISW) over 36 to 48 weeks in 7 steps
Number of subjects: 88
Study 33280227 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal (ISW)
Number of subjects: 88
Study 33280228 — intervention group
Group type: COMPARATOR
Intervention: Office BP threshold of 140/90 mmHg
Number of subjects: 468
Study 33280228 — intervention group
Group type: EXPERIMENTAL
Intervention: Office BP threshold of 130/80 mmHg
Number of subjects: 468
Study 33280228 — intervention group
Group type: EXPERIMENTAL
Intervention: AOBP threshold of 130/80 mmHg
Number of subjects: 468
Study 33280547 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP prediction scores (5 identified scores)
Number of subjects: 683
Study 33280547 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models of scores with biomarkers
Number of subjects: 683
Study 33280547 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected biomarkers
Number of subjects: 683
Study 33280548 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of any SVD (≥1 SVD marker)
Number of subjects: 1419
Study 33280548 — intervention group
Group type: COMPARATOR
Intervention: No SVD
Number of subjects: 1419
Study 33280550 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 361
Study 33280550 — intervention group
Group type: COMPARATOR
Intervention: Medical management only
Number of subjects: 361
Study 33281447 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (ISR)
Number of subjects: 25
Study 33281447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 33281736 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) at 5-8 L/min, 1 hour per session, 3 times daily
Number of subjects: 37
Study 33281950 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endocrine therapy (ET) for 3 (±1) weeks
Number of subjects: 407
Study 33282202 — intervention group
Group type: EXPERIMENTAL
Intervention: LIQ861 (dry-powder inhaled formulation of treprostinil) at doses of 25, 50, 75, 100, 125, and 150 mcg
Number of subjects: 0
Study 33282202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33282388 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab plus chemotherapy
Number of subjects: 30
Study 33282726 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib treatment
Number of subjects: 16
Study 33283229 — intervention group
Group type: EXPERIMENTAL
Intervention: ONSD ultrasound
Number of subjects: 107
Study 33283264 — intervention group
Group type: COMPARATOR
Intervention: GABA analogues (gabapentin and pregabalin)
Number of subjects: 4466
Study 33283264 — intervention group
Group type: COMPARATOR
Intervention: Kappa opioid agonists (nalfurafine)
Number of subjects: 4466
Study 33283264 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 4466
Study 33283264 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast, turmeric, zinc sulfate, topical capsaicin
Number of subjects: 4466
Study 33283580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 37
Study 33283989 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 gene editing of CD34+ hematopoietic stem and progenitor cells
Number of subjects: 0
Study 33283990 — intervention group
Group type: EXPERIMENTAL
Intervention: BCH-BB694 gene therapy (infusion of autologous CD34+ cells transduced with BCH-BB694 lentiviral vector)
Number of subjects: 6
Study 33284392 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen 5Fr PICCs
Number of subjects: 15
Study 33284392 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen 6Fr PICCs
Number of subjects: 15
Study 33284392 — intervention group
Group type: COMPARATOR
Intervention: Triple-lumen 7Fr CICC (reference standard)
Number of subjects: 15
Study 33284423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80-mg every 2 weeks (Q2W)
Number of subjects: 0
Study 33284423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80-mg every 4 weeks (Q4W)
Number of subjects: 0
Study 33284423 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAS40 responders
Number of subjects: 0
Study 33284423 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAS40 response
Number of subjects: 0
Study 33284423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33284467 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-CDS
Number of subjects: 53
Study 33284467 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-GBD
Number of subjects: 53
Study 33284683 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician practices during the pandemic
Number of subjects: 45
Study 33284683 — intervention group
Group type: COMPARATOR
Intervention: Family visits
Number of subjects: 45
Study 33284683 — intervention group
Group type: COMPARATOR
Intervention: Virtual visits
Number of subjects: 45
Study 33284683 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy roles of clinicians
Number of subjects: 45
Study 33284717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand intubation using the marked transmitted glow point (1 cm below the vocal cords)
Number of subjects: 107
Study 33284717 — intervention group
Group type: EXPERIMENTAL
Intervention: Marking point placement
Number of subjects: 107
Study 33284780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Educational Network (GEN) - peer-learning with expert feedback
Number of subjects: 60
Study 33284780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Educational Network (GEN) - peer-learning
Number of subjects: 60
Study 33284780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Educational Network (GEN) - self-learning
Number of subjects: 60
Study 33284780 — intervention group
Group type: COMPARATOR
Intervention: Gamified Educational Network (GEN) - control
Number of subjects: 60
Study 33284946 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete surgical resection
Number of subjects: 0
Study 33284946 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 33284946 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 0
Study 33284946 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (rituximab, steroids), radiotherapy, or embolization
Number of subjects: 0
Study 33284946 — intervention group
Group type: EXPERIMENTAL
Intervention: Further research
Number of subjects: 0
Study 33285144 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation of the defect margin after EMR (EMR-T)
Number of subjects: 179
Study 33285144 — intervention group
Group type: COMPARATOR
Intervention: Conventional EMR
Number of subjects: 179
Study 33285563 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual encoding during memory recall using ultra-high-field (7T) fMRI
Number of subjects: 0
Study 33285563 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual recall task
Number of subjects: 0
Study 33285563 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding-recall similarity analysis
Number of subjects: 0
Study 33285582 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps margin biopsy
Number of subjects: 129
Study 33285582 — intervention group
Group type: COMPARATOR
Intervention: Polypectomy specimen margins
Number of subjects: 129
Study 33287189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, dosage and duration not available
Number of subjects: 0
Study 33287583 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic approaches for follow-up (United States and European Union)
Number of subjects: 574
Study 33287583 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging and blood monitoring (Japan)
Number of subjects: 574
Study 33287583 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring frequency of autoimmune ILDs (Pulmonologists)
Number of subjects: 574
Study 33287583 — intervention group
Group type: COMPARATOR
Intervention: Understanding of progressive fibrosing phenotype
Number of subjects: 574
Study 33287583 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment methods (Pulmonary function tests, diffusing capacity assessments, pulse oximeter measurements)
Number of subjects: 574
Study 33287583 — intervention group
Group type: COMPARATOR
Intervention: Regional differences in treatment approaches
Number of subjects: 574
Study 33287584 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassified group (originally severe AS reclassified as moderate AS)
Number of subjects: 174
Study 33287584 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AS group
Number of subjects: 174